Group 1 - The stock of Jiangsu Haobio Pharmaceutical Co., Ltd. fell by 5.08% on September 23, trading at 141.21 CNY per share, with a total transaction volume of 1.21 billion CNY and a turnover rate of 1.31%, resulting in a total market capitalization of 8.964 billion CNY [1] - The company, established on June 8, 2009, and listed on January 13, 2021, specializes in the research, production, and sales of in vitro diagnostic reagents, with its main revenue sources being reagent sales (89.46%), other sales (5.86%), instrument sales (3.84%), and rental sales (0.85%) [1] Group 2 - According to data from the top ten holdings of funds, one fund under Penghua Fund has a significant position in Haobio, specifically the Penghua Anyue One-Year Holding Period Mixed A Fund (011071), which held 7,962 shares, accounting for 0.58% of the fund's net value, ranking as the tenth largest holding [2] - The Penghua Anyue One-Year Holding Period Mixed A Fund was established on February 9, 2021, with a current scale of 183 million CNY, yielding a return of 10.79% year-to-date, ranking 5,659 out of 8,172 in its category, and a one-year return of 12.47%, ranking 6,599 out of 7,995 [2] - The fund manager, Wang Shiqian, has been in position for 7 years and 182 days, managing total assets of 22.415 billion CNY, with the best fund return during his tenure being 112.28% and the worst being -6.06% [2]

Core Insights - The medical device sector experienced a decline of 0.26% on September 22, with Haobor leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Medical Device Sector Performance - Notable gainers included: - Kangzhong Medical (688607) with a closing price of 31.73, up 10.14% and a trading volume of 59,500 shares, totaling 185 million yuan [1] - Rejing Bio (688068) closed at 181.84, up 4.57% with a trading volume of 31,100 shares, totaling 56.5 million yuan [1] - Zhend Medical (603301) closed at 41.11, up 2.90% with a trading volume of 119,900 shares, totaling 487 million yuan [1] - Major decliners included: - Haobor (688656) closed at 148.77, down 9.22% with a trading volume of 17,100 shares, totaling 26.5 million yuan [2] - Wuzhou Medical (301234) closed at 43.85, down 8.63% with a trading volume of 41,900 shares, totaling 186 million yuan [2] - Jiming Health (603222) closed at 12.47, down 6.45% with a trading volume of 801,100 shares, totaling 102.5 million yuan [2] Capital Flow Analysis - The medical device sector saw a net outflow of 684 million yuan from institutional investors, while retail investors contributed a net inflow of 847 million yuan [2][3] - Key stocks with significant capital flow included: - Mindray Medical (300760) with a net inflow of 79.43 million yuan from institutional investors [3] - Rejing Bio (688068) with a net inflow of 36.79 million yuan from institutional investors [3] - Wuzhou Medical (301234) had a net outflow of 28.64 million yuan from retail investors [3]

Group 1 - The core point of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. experienced a stock decline of 5.11%, with the current share price at 155.50 yuan and a total market capitalization of 9.871 billion yuan [1] - The company was established on June 8, 2009, and went public on January 13, 2021, focusing on the research, production, and sales of in vitro diagnostic reagents [1] - The revenue composition of the company includes 89.46% from reagent sales, 5.86% from other sales, 3.84% from instrument sales, and 0.85% from rental sales [1] Group 2 - From the perspective of fund holdings, one fund under Nuoan Fund has a significant position in Haobo, with Nuoan Jingxin Mixed Fund holding 17,100 shares, accounting for 5.9% of the fund's net value, making it the third-largest holding [2] - The Nuoan Jingxin Mixed Fund was established on December 8, 2015, with a latest scale of 39.4081 million yuan, achieving a year-to-date return of 50.59% and a one-year return of 81.28% [2] - The fund manager, Li Yuliang, has a tenure of 10 years and 203 days, with the best fund return during his tenure being 197.09% and the worst being -86.55% [2]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical and biotechnology industry [6] Core Viewpoints - The pharmaceutical sector has outperformed the CSI 300 index, with the Shenwan Pharmaceutical Biotechnology Index rising by 2.46% from September 1 to September 14, 2025, and by 26.80% year-to-date, surpassing the CSI 300 index by 1.16 percentage points and 11.88 percentage points respectively [1][13] - The current valuation of the pharmaceutical sector stands at 31.58 times (TTM overall method, excluding negative values), with a premium of 148.92% compared to the CSI 300 index [16] - The National Medical Products Administration (NMPA) has announced measures to optimize the review and approval process for innovative drug clinical trials, aiming to complete reviews within 30 working days for eligible applications [20] - The ongoing reforms in drug review and approval systems are expected to enhance the efficiency of clinical trials and accelerate the development of innovative drugs, benefiting companies in this sector [21] Summary by Sections 1. Biweekly Market Review - The pharmaceutical sector's performance from September 1 to September 14, 2025, shows a 2.46% increase, ranking 8th among 31 Shenwan first-level industry indices [11] - Year-to-date, the pharmaceutical sector has increased by 26.80%, also ranking 8th among the indices [13] - The top ten stocks by increase include Zhendemedical (+46.67%), Haooubo (+34.22%), and Kangwei Century (+30.28%), while the top ten stocks by decrease include Shutaishen (-24.15%) and Shanghai Yizhong (-15.39%) [17][18] 2. Important Events - On September 12, 2025, the NMPA released an announcement to support innovative drug development by optimizing the clinical trial review process [20] 3. Industry Insights - The report emphasizes the acceleration of innovative drug development in China, with significant results emerging and ongoing policy optimizations expected to further support this trend [21] - The second half of 2025 is expected to see continued focus on innovative drugs, international expansion, and the clearing of procurement processes, with specific attention to insulin and orthopedic sectors [21]

Market Overview - On September 17, the medical device sector experienced a decline of 0.22%, with Toujing Life leading the drop [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Stock Performance - Notable gainers in the medical device sector included: - Hualan Biological (301093) with a closing price of 39.01, up 5.20% and a trading volume of 85,900 shares, totaling a transaction value of 330 million yuan [1] - Xinhua Medical (600587) closed at 17.16, up 5.08% with a trading volume of 451,500 shares, totaling 767 million yuan [1] - Haooubo (688656) closed at 168.52, up 5.00% with a trading volume of 16,600 shares, totaling 272 million yuan [1] - Conversely, the following companies saw significant declines: - Toujing Life (300642) closed at 24.55, down 7.53% with a trading volume of 168,900 shares, totaling 426 million yuan [2] - Jimin Health (603222) closed at 13.22, down 4.06% with a trading volume of 748,900 shares, totaling 995 million yuan [2] - Meihua Medical (301363) closed at 27.31, down 2.95% with a trading volume of 153,300 shares, totaling 422 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 894 million yuan from institutional investors, while retail investors contributed a net inflow of 818 million yuan [2] - Notable capital flows included: - Haooubo (688656) with a net inflow of 39.06 million yuan from institutional investors, but a net outflow of 23.69 million yuan from speculative funds [3] - Xinhua Medical (600587) had a net inflow of 38.89 million yuan from institutional investors, with a net outflow of 64.90 million yuan from speculative funds [3] - Hualan Biological (301093) recorded a net inflow of 24.68 million yuan from institutional investors, while retail investors saw a net outflow of 25.99 million yuan [3]

江苏浩欧博生物医药股份有限公司（688656） 2025 年第三次临时股东大会会议资料 江苏浩欧博生物医药股份有限公司 2025 年第三次临时股东大会会议资料 二〇二五年九月 江苏浩欧博生物医药股份有限公司（688656） 2025 年第三次临时股东大会会议资料 江苏浩欧博生物医药股份有限公司（688656） 2025 年第三次临时股东大会会议资料 2025 年第三次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的顺 利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规 则》以及《江苏浩欧博生物医药股份有限公司章程》（以下简称"《公司章程》"）、《江 苏浩欧博生物医药股份有限公司股东大会议事规则》等相关规定，江苏浩欧博生物医药股 份有限公司（以下简称"公司"）特制定 2025 年第三次临时股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人员将对 出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，出席会议的股 东及股东代理人须在会议召 ...

Group 1 - The core viewpoint of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. has seen a stock price increase of 5.3%, reaching 169.00 CNY per share, with a total market capitalization of 10.728 billion CNY [1] - The company, established on June 8, 2009, specializes in the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its main business revenue [1] - Other revenue sources include 5.86% from other sales, 3.84% from instrument sales, and 0.85% from rental sales [1] Group 2 - Huafu Fund has a significant holding in Haobo Bio, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 32,000 shares, representing 5.87% of the fund's net value [2] - The fund has achieved a year-to-date return of 64.07%, ranking 409 out of 8172 in its category, and a one-year return of 69.47%, ranking 1687 out of 7980 [2] - The fund manager, Liao Qingyang, has been in charge for 3 years and 313 days, with the best fund return during this period being 43.34% [2]

9月15日，浩欧博跌5.42%，截至发稿，报157.01元/股，成交1.06亿元，换手率1.05%，总市值99.67亿 元。 申万菱信医药先锋股票A（005433）基金经理为姚宏福。 截至发稿，姚宏福累计任职时间3年60天，现任基金资产总规模1.33亿元，任职期间最佳基金回 报-23.18%， 任职期间最差基金回报-24.16%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，江苏浩欧博生物医药股份有限公司位于苏州工业园区东堰里路9号，成立日期2009年6月8 日，上市日期2021年1月13日，公司主营业务涉及从事体外诊断试剂的研发、生产和销售。主营业务收 入构成为：试剂销售89.46%，其他销售5.86%，仪器销售3.84%，租赁销售0.85%。 从基金十大重仓股角度 数据显示，申万菱信基金旗下1只基金重仓浩欧博。申万菱信医药先锋股票A（005433）二季度持有股 数5.61万股，占基金净值比例为5.74%，位居第六大重仓股。根据测算，今 ...

9月12日，浩欧博涨5.46%，截至发稿，报154.50元/股，成交2.06亿元，换手率2.23%，总市值98.08亿 元。浩欧博股价已经连续4天上涨，区间累计涨幅12.93%。 资料显示，江苏浩欧博生物医药股份有限公司位于苏州工业园区东堰里路9号，成立日期2009年6月8 日，上市日期2021年1月13日，公司主营业务涉及从事体外诊断试剂的研发、生产和销售。主营业务收 入构成为：试剂销售89.46%，其他销售5.86%，仪器销售3.84%，租赁销售0.85%。 从基金十大重仓股角度 截至发稿，李玉良累计任职时间10年193天，现任基金资产总规模3940.75万元，任职期间最佳基金回报 178.86%， 任职期间最差基金回报-86.55%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，诺安基金旗下1只基金重仓浩欧博。诺安景鑫混合（002145）二季度持有股数1.71万股，占 基金净值比例为5.9%，位居第三大重仓股。根据测算，今日浮盈赚取 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-054 江苏浩欧博生物医药股份有限公司 关于为董事、监事及高级管理人员 购买责任保险的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 江苏浩欧博生物医药股份有限公司（以下简称"公司"）于2025年9月9日召开第三届董事会第二十七次会 议及第三届监事会第二十一次会议，审议《关于为董事、监事及高级管理人员购买责任保险的议案》。 因公司全体董事、监事为被保险对象，基于谨慎性原则，全体董事、监事已回避表决，上述议案将直接 提交公司2025年第三次临时股东大会进行审议。 为保障广大投资者利益、降低公司运营风险，同时促进公司管理层充分行使权利、履行职责，根据《上 市公司治理准则》等相关规定，公司拟为公司及控股子公司董事、监事及高级管理人员购买责任保险， 具体方案如下： 1、投保人：江苏浩欧博生物医药股份有限公司 2、被保险人：公司及控股子公司全体董事、监事及高级管理人员 3、责任限额：不超过人民币5,000万元（具体以保险合同为准） 4、保费金额：不超过人民币25万元 ...